Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more
Mangoceuticals, Inc. Common Stock (MGRX) - Total Assets
Latest total assets as of September 2025: $16.53 Million USD
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) holds total assets worth $16.53 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mangoceuticals, Inc. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how Mangoceuticals, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Mangoceuticals, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Mangoceuticals, Inc. Common Stock's total assets of $16.53 Million consist of 0.5% current assets and 99.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.23 Million | 99.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Mangoceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mangoceuticals, Inc. Common Stock's current assets represent 0.5% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2024, down from 100.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 99.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 99.1% of total assets.
Mangoceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of Mangoceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
UCrest Bhd
KLSE:0005
|
Malaysia | RM48.46 Million |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
China | CN¥265.74 Million |
|
BIT Computer Co. Ltd
KQ:032850
|
Korea | ₩82.38 Billion |
|
ezCaretech Co. LTD
KQ:099750
|
Korea | ₩56.71 Billion |
|
SyntekaBio Inc
KQ:226330
|
Korea | ₩33.49 Billion |
|
Carelabs Co.Ltd
KQ:263700
|
Korea | ₩105.15 Billion |
|
Shanghai Kingstar Winning Software
SHE:300253
|
China | CN¥8.35 Billion |
|
Longmaster Information Tech
SHE:300288
|
China | CN¥1.33 Billion |
Mangoceuticals, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Mangoceuticals, Inc. Common Stock generates 0.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Mangoceuticals, Inc. Common Stock is currently not profitable relative to its asset base.
Mangoceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.74 | 0.07 | 0.01 |
| Quick Ratio | 0.74 | 0.07 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-206.05K | $ -1.29 Million | $ -138.33K |
Mangoceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Mangoceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.37 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 1362.8% |
| Total Assets | $15.37 Million |
| Market Capitalization | $3.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mangoceuticals, Inc. Common Stock's assets below their book value (0.24 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Mangoceuticals, Inc. Common Stock's assets grew by 1362.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mangoceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual total assets of Mangoceuticals, Inc. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $15.37 Million | +1362.75% |
| 2023-12-31 | $1.05 Million | +4.74% |
| 2022-12-31 | $1.00 Million | +4349.17% |
| 2021-12-31 | $22.55K | -- |